The authors reported that public bulk lung transcriptomic datasets reproducibly identified a POSTN-enriched extracellular matrix remodeling program in lungs from patients with idiopathic pulmonary fibrosis. Short statement: POSTN marked a consistent fibrotic program across datasets. Longer explanation: single-cell and donor-level pseudobulk analyses then refined that signal, showing that a PIEZO1/YAP activity–related transcriptional signature was co-enriched specifically in POSTN-positive fibroblast and myofibroblast compartments, which the investigators presented as evidence that mechanosensitive signaling may track with POSTN-defined fibroblast states.
Data indicated a compartmentalized transcriptional relationship rather than a diffuse lung-wide expression pattern. The study team observed the co-enrichment at both single-cell resolution and in aggregated donor-level analyses, suggesting the association is reproducible across analytic scales. The abstract did not report the precise gene lists, enrichment statistics, or the criteria used to define POSTN-positive compartments; those methodological details were not provided in the abstract text.
The study group used a bleomycin-induced pulmonary fibrosis model to examine whether the transcriptomic associations were mirrored at the tissue level. They reported that fibrotic lung regions showed upregulation of Postn, induction of Piezo1, and increased nuclear localization of Yap. Simple fact: all three markers increased in fibrotic areas. More nuance: by tying transcriptional co-enrichment to histologic and protein-localization changes in an experimental model, the authors argued for a consistent link between POSTN-enriched states and mechanotransduction signaling.
The team also tested a pharmacologic intervention in vivo. Verteporfin, applied as an inhibitor of Yap/TEAD-associated transcription according to the authors, attenuated multiple readouts of fibrosis in the bleomycin model: the investigators reported reductions in collagen deposition, hydroxyproline accumulation, profibrotic gene expression, and induction of Yap target proteins. The abstract does not state verteporfin dosing, treatment timing, or toxicity monitoring details; those specifics were not reported in the abstract and therefore cannot be summarized here.
In cell-based experiments, the study team stimulated lung fibroblasts with transforming growth factor–β1 (TGF-β1) to model activation. Verteporfin suppressed fibroblast migration, reduced Yap nuclear localization, and lowered profibrotic marker expression at concentrations the authors described as non-cytotoxic. The authors reported that knockdown of Piezo1 or Yap1 diminished TGF-β1–induced fibroblast activation, providing loss-of-function evidence that both molecules contribute to the activation phenotype.
Mechanistic directionality was probed: Piezo1 knockdown decreased Yap nuclear localization and reduced activity in a Yap/TEAD reporter assay. The investigators further reported that expression of an active YAP construct partially rescued profibrotic gene expression following Piezo1 knockdown. That pattern—loss of Piezo1 reduces YAP activity, while active YAP reinstates part of the profibrotic program—supports the authors’ interpretation that PIEZO1 signals upstream of YAP/TEAD-dependent transcription in fibroblast activation.
The abstract summarizes multiple intervention modalities—genetic knockdown and pharmacologic inhibition—and links molecular changes to functional outputs such as migration and profibrotic marker induction. The authors emphasized that these interventions converged on reduced markers of fibroblast activation and extracellular matrix remodeling.
The authors concluded that a POSTN-enriched fibrotic fibroblast state is associated with enhanced PIEZO1–YAP/TEAD signaling, and they presented functional data supporting a role for that axis in fibroblast activation and fibrotic lung remodeling. The abstract, however, did not report several methodological specifics. It did not list exact sample sizes, the criteria for dataset inclusion, quantitative effect sizes, verteporfin dosing regimens or timing, nor detailed statistical outputs. The abstract also did not provide information on potential off-target effects of verteporfin in vivo or in vitro, nor on long-term functional outcomes beyond molecular and histologic readouts in the bleomycin model.
These omissions leave open clinical and translational questions that the abstract does not answer: how broadly conserved is the POSTN–PIEZO1–YAP/TEAD axis across patient subgroups, what are the therapeutic windows for targeting YAP/TEAD in vivo, and whether PIEZO1 modulation would have acceptable safety and specificity profiles in human disease. The abstract did not claim to resolve those issues; it reported reproducible transcriptomic associations and convergent functional experiments but did not provide the full methodological or dosing detail required to assess translational readiness.
Authors noted no competing interests in the conflict-of-interest statement. For full experimental methods, dosing, and statistical details, consult the full text of the published article; those specifics were not included in the abstract and therefore are not summarized here.